Samir Gharib joined Stemedica Cell Technologies as Chief Financial Officer in 2018. Mr. Gharib brings 15 years of experience as a seasoned financial executive in the biotechnology and life science industries. He is widely regarded as a savvy strategic advisor to CEOs and Boards on issues ranging from financing strategy, pipeline evaluation, exit strategy, investor relations and corporation communications to commercialization. Over the course of his career, Mr. Gharib has raised over $500 million from the private and public capital markets, including an IPO, to fund late-stage clinical development, pipeline expansion, and commercialization. He is passionate about building great teams and delivering value to patients, patient care providers, shareholders, corporate partners, and employees through the development and commercialization of novel therapeutics.

Prior to Stemedica, Mr. Gharib founded and served as Managing Director of Benchmark Financial Partners, a financial advisory firm providing interim/fractional CFO services, transaction advisory services, and financial operations support. Mr. Gharib grew and established Benchmark as a premier financial consulting and advisory practice in the Silicon Valley with experienced financial leaders helping life science and technology companies solve their toughest problems, navigate through near term inflection points, evaluate their strategic options and make better business decisions.

Prior to founding Benchmark, Mr. Gharib served as Vice President of Finance and Administration for Revance Therapeutics (NASDAQ: RVNC), where he oversaw the finance, accounting, legal and information technology functions. Mr. Gharib led Revance’s 2014 IPO and raised $450+ million from the capital markets while scaling the organization for growth and commercial-stage readiness. Mr. Gharib also actively participated in the closings of multiple research and collaboration arrangements. Today, Revance is solidly positioned to launch its leading drug candidate, RT002 for the treatment of glabellar lines.

Prior to Revance, Mr. Gharib served as Director of Finance and Corporate Controller for Talon Therapeutics (OTCQB: TLON), a biopharmaceutical company focused on the development of small-molecule therapeutics for oncologic indications. At Talon, Mr. Gharib raised $70+ million from Warburg Pincus and Deerfield to fund NDA approval activities, label expansion trials, and commercial launch for Marqibo®. Mr. Gharib also held a key leadership role in commercialization efforts for Marqibo®. In 2013, he led the review of strategic options for the company, culminating in the acquisition of Talon by Spectrum Pharmaceuticals (NASDAQ: SPPI). Prior to Talon, Mr. Gharib spent several years in management consulting with CRC, a management consulting firm and member of the BDO Alliance, and with KPMG LLP in their Assurance and Forensic Advisory Practices.

Mr. Gharib serves on the Board of Directors of Cancer CAREpoint, an organization that provides personalized counseling, assistance, resources and education to Silicon Valley cancer patients, families and caregivers and heads the organization’s corporate development efforts. Mr. Gharib earned a Bachelor of Science and MBA from the Haas School of Business at U.C. Berkeley and is an active CPA licensed in the State of California.